The National Institute for Health and Care Excellence (NICE) decision pertains to patients who have already completed chemotherapy or appropriate targeted therapy for those with an EGFR or ALK aberration.

For clinically significant prostate cancer (intermediate risk or high risk based on NICE classification), the incidence remained significantly higher in MSH2 carriers versus controls (3.6 vs 0.0%) but the difference was not significant for MSH6 carriers versus controls (2.2 vs 0.0%).

The BERENICE investigators report a low incidence of cardiac events with the use of pertuzumab–trastuzumab-based neoadjuvant and adjuvant regimens in patients with HER2-positive, early breast cancer after 5 years of follow-up.

Kirwan and colleagues point out that just 19% of the participants who received COVID-altered treatment were managed in a way “that was clearly outside the pre-COVID breast cancer NICE guidelines […], implying that breast cancer oncological outcomes in this study are unlikely to be negatively impacted (although the psychological impact of reconstruction omission is yet to be determined).”

Read more on these US FDA and UK NICE approvals here

medwireNews : The UK’s NICE has recommended use of maintenance durvalumab therapy in patients with unresectable non-small-cell lung cancer (NSCLC) who have previously received concurrent platinum-based chemotherapy and radiation.

Presenting the phase II results at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, Marc Pujalte-Martin (Centre Antoine Lacassagne, Nice) explained that metformin has been associated with a reduced risk for prostate cancer incidence and with improved outcomes in patients with prostate cancer and diabetes.

. © 2019 Springer Healthcare part of the Springer Nature group See also:  Atezolizumab, larotrectinib approvals announced by FDA Atezolizumab receives NICE recommendation for NSCLC Atezolizumab receives positive opinion for advanced urothelial cancer, NSCLC

. © 2019 Springer Healthcare part of the Springer Nature group See also: Atezolizumab-platinum-based chemotherapy NSCLC regimens advance to phase III trials Atezolizumab receives NICE recommendation for NSCLC Larotrectinib ‘potential standard of care’ for adult, pediatric, TRK fusion tumors Pembrolizumab receives agnostic approval for MSI-H/dMMR tumours

Women at high risk (≥8% 10-year risk) in the UK can have more frequent National Institute for Health and Care Excellence (NICE)-approved screening and access to NICE-approved prevention medication such as tamoxifen or anastrozole that can reduce breast cancer risk by 35–50%.

This compared with corresponding values of 0.73, 59%, and 81% for a clinical parameters test derived from the UK’s NICE guidelines for endoscopy referral, say George Hanna (Imperial College London, UK) and co-authors.

. © 2018 Springer Healthcare part of the Springer Nature group See also:  Atezolizumab boosts survival in metastatic nonsquamous NSCLC 'Encouraging' results with post-progression atezolizumab in NSCLC Atezolizumab receives NICE recommendation for NSCLC Atezolizumab receives positive opinion for advanced urothelial cancer, NSCLC 

medwireNews : The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending that three multikinase inhibitor agents be made available for patients with thyroid cancer.

Henri Montaudié, from Nice University Hospital in France, and colleagues, who report data on 15 patients in JAMA Dermatology , say, however, that “[p]rospective studies with larger samples of patients are needed to confirm the interest of this combination.”